2025-12-31 - Analysis Report
Okay, here's a breakdown of the Recursion Pharmaceuticals (RXRX) data, including simple numbers, analysis, and a comprehensive summary.

**1) Return Rate Comparison**

*   **Ticker:** RXRX
*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.
*   **RXRX Cumulative Return:** -33.45%
*   **S&P 500 (VOO) Cumulative Return:** 44.20%
*   **Divergence:** -76.4 (Relative Divergence: 0.0)

**Analysis:**

*   RXRX has significantly underperformed the S&P 500. The -76.4% divergence indicates a substantial difference in cumulative returns. The Relative Divergence of 0.0 suggests the current divergence is at the lowest point of its historical range.
*   The negative cumulative return for RXRX indicates a loss of value over the period analyzed, while the S&P 500 has seen substantial gains.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2 | 5.1    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1  | 3.5    |
| 2023-2025  | 9.0%   | 80.0% | -58.0% | 0.1  | 2.1    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has declined over the three periods, from 22.0% to 9.0%, showing decelerating growth.
*   **MDD:** The Maximum Drawdown (MDD) remains high, consistently around 80%, indicating significant risk and volatility.
*   **Alpha:** Alpha, which measures performance relative to the benchmark, has deteriorated significantly from 26.0% to -58.0%, suggesting underperformance compared to the market.
*   **Beta:** Beta values around 0 suggest the stock's price movements are not strongly correlated with the overall market.
*   **Cap(B):** The market capitalization has decreased from 5.1B to 2.1B, reflecting a decline in the company's value.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.11
*   **Previous Close:** 4.13
*   **Change:** -0.48%
*   **5-day SMA:** 4.25
*   **20-day SMA:** 4.464
*   **60-day SMA:** 4.9403

**Analysis:**

*   The current price is below all three Simple Moving Averages (SMAs), indicating a downtrend.  The 5-day SMA is the closest, but the 20-day and 60-day SMAs are significantly higher, reinforcing the bearish sentiment.
*   The slight decrease from the previous close suggests continued downward pressure.

**3) Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 33.33
*   **PPO:** -0.4349
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -3.3 (Decreasing trend)
*   **Expected Return (%):** -569.7%

**Analysis:**

*   **MRI:** While MRI suggests high investment recommendation, it should be cautiously interpreted alongside other indicators due to conflicting signals.
*   **RSI:** The RSI of 33.33 suggests the stock is nearing oversold territory, potentially indicating a possible (but not guaranteed) rebound.
*   **PPO:** The negative PPO indicates the short-term moving average is below the long-term moving average, further confirming the downtrend.
*   **Hybrid Signal:** The Hybrid Signal is a model-driven signal based on the MRI, suggesting 100% cash allocation for a buy (225 shares), which is "very safe". It recommends monthly investment of 1.7% of total investment.
*   **Recent Relative Divergence Change:** The negative change indicates a short-term decline relative to the comparison stock (S&P 500).
*   **Expected Return:** The very low expected return implies a very negative outlook.

**4) Recent News & Significant Events**

*   **Negative Headlines:** The news headlines paint a mixed to negative picture: Insider selling, CEO transition, a stock plummet, and negative sentiment.
*   **Positive Note:** A JPMorgan upgrade and trial data gains provided a brief surge, but recent news leans bearish.
*   **Analyst Activity:** Nikko Asset Management Americas Inc. sold shares of Recursion Pharmaceuticals.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.50, ~Hold)
*   **Opinions:** 7 analysts
*   **Target Price:** Avg: 7.00 / High: 11.00 / Low: 3.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:**

*   Despite the negative price action, the analyst consensus is a "Buy" (leaning towards "Hold"). This suggests some analysts see long-term potential despite the current challenges. However, the target price range is wide, indicating uncertainty. The average target price is significantly higher than the current price, indicating potential upside if analysts' predictions hold true.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출    |
|------------|--------|---------|
| 2025-11-05 | -0.36  | 0.01 B$ |
| 2025-08-05 | -0.41  | 0.02 B$ |
| 2025-05-05 | -0.5   | 0.01 B$ |
| 2024-11-06 | -0.34  | 0.03 B$ |
| 2025-11-05 | -0.34  | 0.03 B$ |

**Analysis:**

*   The company has consistently reported negative Earnings Per Share (EPS), which indicates a lack of profitability.
*   Revenue has fluctuated but generally remains low (in the millions of dollars), failing to offset the losses.
*   There appears to be a duplicate entry for 2025-11-05, which needs to be corrected for accurate analysis. However, even if we consider only one of them, the trend remains the same - negative EPS and low revenue.

**6) Financial Information**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.00B    | -194.74%      |
| 2025-06-30   | $0.02B    | -5.54%        |
| 2025-03-31   | $0.01B    | -47.31%        |
| 2024-12-31   | $0.00B    | -183.62%      |
| 2024-09-30   | $0.03B    | 53.69%        |

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $1.05B    | -15.50%   |
| 2025-06-30   | $0.92B    | -18.70%   |
| 2025-03-31   | $0.93B    | -21.68%   |
| 2024-12-31   | $1.03B    | -17.29%   |
| 2024-09-30   | $0.52B    | -18.27%   |

**Analysis:**

*   **Revenue:** Revenue is inconsistent and often very low, with some quarters showing zero revenue.
*   **Profit Margin:** The profit margin is largely negative, indicating significant losses. The one positive margin (53.69% in 2024-09-30) is an outlier.
*   **Equity:** Equity has fluctuated but generally remains above $0.9 billion.
*   **ROE:** Return on Equity (ROE) is consistently negative, reinforcing the company's lack of profitability.

**7) Comprehensive Analysis (Summary)**

Recursion Pharmaceuticals (RXRX) is facing significant challenges. The stock has underperformed the S&P 500 significantly. Technical indicators suggest a downtrend, although the RSI indicates it may be approaching oversold conditions. Recent news and events have been mixed, with more negative headlines than positive.  The company consistently reports negative EPS and has inconsistent revenue and profit margins. The company is burning through its equity, although the current equity levels are still relatively high.

**Investment Recommendation:**

Based on the data provided, an investment in RXRX appears **very risky**. While some analysts maintain a "Buy" rating, the negative financial performance, poor stock performance relative to the market, and negative news flow warrant extreme caution. The MRI of 0.9 should be interpreted cautiously alongside these negative signals. A potential investor would need to conduct thorough due diligence, understand the long-term potential of the company's technology, and be prepared for significant volatility and potential losses. The extremely negative expected return is a major red flag.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.